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OBJECTIVE: To determine whether or not subtle differ-
ences between risperidone and olanzapine, two similarly-
efﬁcacious medications, are reﬂected in health care
utilization patterns, and therefore, costs, in patients with
schizophrenia receiving usual care. METHODS: A retro-
spective cohort study was conducted from the payer per-
spective in two group model managed care organizations.
Analysis of covariance and logistic regression were used
to identify outpatient cost and hospitalization differences
respectively, while adjusting for variables that may inde-
pendently inﬂuence mental health utilization and choice
of atypical agent. Patients ages 18–64 initiating risperi-
done or olanzapine between January 1997 and December
2000 diagnosed with schizophrenia or schizoaffective 
disorder in the pre-initiation year were included if they
received no atypical antipsychotics in the previous year
and were continuously enrolled one year pre through one
year post initiation. Utilization units were transformed
into 2001 costs at one site. The total post-initiation year
outpatient mental health cost derived included all mental
health outpatient visits (including urgent care) and med-
ications, and tests related to olanzapine or risperidone
monitoring. The relationship between drug exposure and
hospitalization was explored using logistic regression. 
An intent-to-treat analysis was performed. RESULTS:
Patients receiving risperidone were less costly in the post-
initiation year than patients receiving olanzapine. The
results were signiﬁcant (p < 0.05) controlling for age,
gender, coverage type, total mental health outpatient costs
in the year prior to initiation, study site, index year,
mental health comorbidities, and mental health hospital-
ization in the pre-initiation year. Seventeen percent of
olanzapine and 21% of risperidone patients were hospi-
talized in the year post initiation, a difference that was
not statistically signiﬁcant. CONCLUSIONS: Prescribers
should consider using risperidone before using olanzap-
ine when initiating therapy in a patient with schizophre-
nia who has no contraindications to either medication.
More study is needed to determine the relation-
ship between atypical choice and mental health 
hospitalization.
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OBJECTIVE: To compare pharmacotherapy patterns 
and treatment outcomes for olanzapine- versus quetia-
pine-treated hospitalized patients with schizophrenia.
METHODS: Hospitalized olanzapine- and quetiapine-
treated patients discharged with schizophrenia (ICD9:
295.xx) between 01/1999 and 09/2001 were identiﬁed
using Premier’s PerspectiveTM database, the largest U.S.
hospital drug utilization database. Outcome measures
include use of other antipsychotics, mood stabilizers, anti-
depressants, anxiolytics, and hypnotics; length of stay
(LOS); and total treatment costs were analyzed by regres-
sions, controlling diagnoses, illness severity, patient and
institution characteristics. RESULTS: Of 9433 patients
(54.8% male, mean age 41.5 years), 6699 were olanzap-
ine-treated and 2734 quetiapine-treated. After adjusting
for confounding factors, olanzapine-treated patients used
fewer psychotropic agents (-0.36, p < 0.0001) and were
less likely to switch to or augment with other atypical
antipsychotics (odds ratio (OR) = 0.71, 95% conﬁdence
interval (CI) = 0.62 - 0.81). Olanzapine-treated patients
were less likely to be treated with typical antipsychotics
(OR = 0.77, CI = 0.70 - 0.85), mood-stabilizers (OR =
0.84, CI = 0.77 - 0.93), anxiolytics (OR = 0.67, CI = 0.60
- 0.74), or anti-Parkinsonian agents (OR = 0.87, CI =
0.79 - 0.96). There was no between-group difference in
antidepressant or hypnotic use. Total costs for olanzap-
ine-treated patients were lower (-$678, p < 0.0001) as
the result of shorter LOS (-11.4%, p < 0.0001). CON-
CLUSIONS: Compared to quetiapine, olanzapine treat-
ment for hospitalized patients with schizophrenia was
associated with more favorable pharmacotherapy pat-
terns, shorter LOS, and lower costs.
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OBJECTIVES: To examine treatment patterns and
analyze differences in health services utilization and costs
for subjects receiving risperidone, olanzapine or quetiap-
ine. METHODS: This study used administrative claims
data to identify continuously enrolled subjects prescribed
atypical antipsychotics between January 1, 2000 and
December 31, 2000. Subjects were assigned to a diag-
nostic category based on the appearance of two or more
ICD-9 codes for schizophrenia, affective disorder, 
dementia, anxiety or childhood disorders during the
study period. Duration of therapy, compliance, daily
dose, daily average consumption and concomitant med-
ication use were analyzed descriptively. Subjects were
propensity score matched on baseline characteristics for
the purpose of comparing health services utilization and
cost by site of service. RESULTS: Of 6471 study subjects,
average annual days of therapy were nearly equal
between drug groups (184–186 days). However, average
annual days of therapy varied widely by diagnostic con-
dition (181 days for anxiety, 270 days for schizophrenia).
Concomitant use of psychotropic medication was
common for all 3 drugs (81%). Subjects receiving risperi-
done had an average daily dose below the recommended
target dose for schizophrenia as did olanzapine subjects
with bipolar disorder. Daily average consumption
increased slightly for risperidone and quetiapine subjects
